Evidence map›Paper›PMID 41630692›Full record

ReviewChinese medical journal2026

Microbiota in pancreatic ductal adenocarcinoma progression and therapy: The hidden players.

Xiulin Hu, Fanyang Kong, Jiayu Chen, Zhaoshen Li, Zhenzhai Cai, Xiangyu Kong

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Chinese medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiulin HuDepartment of Gastroenterology, Changhai Hospital, National Key Laboratory of Immunity and Inflammation, Naval Medical University, Shanghai 200433, China.
Fanyang KongDepartment of Gastroenterology, Changhai Hospital, National Key Laboratory of Immunity and Inflammation, Naval Medical University, Shanghai 200433, China.
Jiayu ChenShanghai Institute of Pancreatic Diseases, Shanghai 200433, China.
Zhaoshen LiShanghai Institute of Pancreatic Diseases, Shanghai 200433, China.
Zhenzhai CaiDepartment of Gastroenterology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China.
Xiangyu KongDepartment of Gastroenterology, Changhai Hospital, National Key Laboratory of Immunity and Inflammation, Naval Medical University, Shanghai 200433, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractPancreatic ductal adenocarcinoma (PDAC), the deadliest epithelial malignancy, is increasingly prevalent and contributes significantly to cancer-related mortality. Research over the past decade has demonstrated that microbiota may play a pivotal role in both PDAC oncogenesis and its resistance to chemotherapy. Emerging preclinical and clinical data highlight the impact of microbiota on therapeutic outcomes in PDAC patients. This review systematically explores the role and underlying mechanisms of microbiota in PDAC, with a particular focus on their clinical implications and translational potential in disease progression and therapeutic responses. Finally, this review addresses the potential of microbiome-based therapies to enhance the efficacy of PDAC treatments.

Indexed as

Carcinoma, Pancreatic DuctalMicrobiotaPancreatic NeoplasmsAnimalsDisease ProgressionHumansMetabolitesMicrobiotaPancreatic cancerTherapeutic resistance

Identifiers

PMID41630692
PMCPMC12999093

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.